Lifeward Ltd. (NASDAQ:LFWD) is a key player in the medical technology sector, focusing on enhancing the lives of individuals with physical limitations. The company is set to release its quarterly earnings on March 18, 2026. Wall Street anticipates an earnings per share (EPS) of -$0.96 and revenue of approximately $7.87 million for this period.
Despite a negative EPS forecast, LFWD's financial metrics provide a deeper insight into its current standing. The company has a negative price-to-earnings (P/E) ratio of -0.33, indicating it is not currently profitable. This is further emphasized by a negative earnings yield of -3.05%, highlighting ongoing profitability challenges.
LFWD's price-to-sales ratio is 0.46, meaning investors pay $0.46 for every dollar of sales. This suggests a relatively low valuation compared to its sales. The enterprise value to sales ratio is slightly lower at 0.38, indicating a lower valuation when accounting for debt and cash.
The enterprise value to operating cash flow ratio is negative at -0.53, reflecting difficulties in generating positive cash flow from operations. However, LFWD maintains a low debt-to-equity ratio of 0.019, showing minimal reliance on debt. The current ratio of 1.92 suggests a strong ability to cover short-term liabilities with short-term assets.
